Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor.
Journal
CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
30
08
2021
received:
14
06
2021
accepted:
01
09
2021
pubmed:
30
9
2021
medline:
5
4
2022
entrez:
29
9
2021
Statut:
ppublish
Résumé
This analysis was conducted to assess exposure-response relationships for efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed categorically by overall response rate (ORR) with Response Evaluation Criteria in Solid Tumors version 1.1 and longitudinally (changes in tumor size and volume). Safety included hepatic parameters (i.e., alanine aminotransferase [ALT], aspartate aminotransferase [AST], and total bilirubin). Average pexidartinib concentration (C
Identifiants
pubmed: 34585528
doi: 10.1002/psp4.12712
pmc: PMC8592513
doi:
Substances chimiques
Aminopyridines
0
Pyrroles
0
pexidartinib
6783M2LV5X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1422-1432Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Daiichi Sankyo, Inc.
Informations de copyright
© 2021 Daiichi Sankyo, Inc. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):171-92
pubmed: 11381569
J Clin Pharmacol. 2021 Apr;61(4):480-492
pubmed: 33043474
Lancet. 2019 Aug 10;394(10197):478-487
pubmed: 31229240
CPT Pharmacometrics Syst Pharmacol. 2014 May 07;3:e113
pubmed: 24806032
Br J Clin Pharmacol. 2015 Jan;79(1):56-71
pubmed: 24134068
N Engl J Med. 2015 Jul 30;373(5):428-37
pubmed: 26222558
J Clin Oncol. 2018 Jan 10;36(2):202-209
pubmed: 29220303
Cancer Chemother Pharmacol. 2016 Mar;77(3):459-76
pubmed: 26811176
CPT Pharmacometrics Syst Pharmacol. 2015 Jan;4(1):e00016
pubmed: 26225225
CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1422-1432
pubmed: 34585528